A Japan-based drug manufacturer won’t be required to alter its allocation of a scarce pain treatment drug to fulfill its contracts with an American drug distributor, Vice Chancellor Sam Glasscock III has ruled.

There would have been no way to enforce Takeda Pharmaceuticals’ compliance with an injunction requested by AbbVie Endocrine Inc., Glasscock wrote in a post-trial opinion.